On July 1, 2025, Ashley Moody cast one of the 50 votes that passed the One Big Beautiful Bill Act, which exempts more drugs from Medicare price negotiation; the cancer drugs Keytruda and Opdivo were not chosen for negotiation as a result. The same night, Moody voted against an amendment to cut Medicare drug prices in half, and in April 2026 she voted against capping U.S. drug prices at European and Canadian levels.
Moody also voted to confirm Martin Makary to run the Food and Drug Administration, where layoffs left inspectors of the foreign factories that make many U.S. drugs saying "You can't inspect as many sites." Florida has 5,133,537 Medicare enrollees.
Ashley Moody's Votes on Prescription Drug Prices and the FDA
- Moody Cast a Deciding Vote to Exempt More Drugs From Medicare Price Negotiation in July 2025. On July 1, 2025, Ashley Moody voted for H.R. 1, which passed 50 to 50 with the Vice President breaking the tie. Its section 71203 widens the orphan-drug exemption from Medicare negotiation. The Congressional Budget Office estimates the change costs Medicare an additional $8.8 billion, and it covers drugs with $17.5 billion in total spending by Medicare and beneficiaries in 2023. Selection of Keytruda and Opdivo has been delayed beyond 2026; KFF estimates a typical negotiated discount on Keytruda would mean annual savings on cost-sharing liability of around $3,300 for the seniors who take it.
- Moody Voted Against Cutting Medicare Drug Prices in Half in July 2025. On July 1, 2025, during the debate on H.R. 1, Moody voted no on Senator Bernie Sanders's amendment "To cut the price of prescription drugs under Medicare in half and expand Medicare to cover dental, vision, and hearing." All 53 Republican senators voted no. A majority of the public, 59%, is worried about affording prescription drugs, the largest share since KFF began asking in 2018.
- Moody Voted Against Capping U.S. Drug Prices at European and Canadian Levels in April 2026. On April 23, 2026, Moody voted no on waiving budget rules for an amendment "To reduce the price of prescription drugs in the United States by more than 50 percent by adopting Most Favored Nation drug pricing so that the American people pay no more for prescription drugs than Europeans or Canadians." It got 49 votes, short of the 60 needed. Seven in 10 adults, 72%, say there is not enough government regulation limiting drug prices.
- Moody Voted Against Auditing the Administration's Confidential Drug-Price Deals in April 2026. On April 23, 2026, Moody voted no on an amendment calling for a Government Accountability Office study of the "economic consequences of private or confidential drug pricing agreements" between federal agencies and drug makers. It failed 48 to 50. KFF reports that the details of these deals are confidential and not available to the public.
- Moody Voted Against Blocking Higher Drug Costs for Seniors and Against Ending Price Gouging in 2025. On April 5, 2025, Moody voted no on a point of order "against legislation that would increase drug costs for seniors and people with disabilities on Medicare," which failed 49 to 50. On February 21, 2025, she voted no on an amendment for a reserve fund "relating to ending price gouging on prescription drugs," which failed 49 to 51. The law that followed is the one whose orphan-drug change raises Medicare drug spending.
- Moody Voted to Confirm Martin Makary, Whose FDA Lost Drug-Factory Inspectors, in March 2025. On March 25, 2025, Moody voted to confirm Martin Makary as commissioner of food and drugs. Weeks later, layoffs at his agency left the inspectors who check the foreign factories that make many generic drugs saying "You can't inspect as many sites," ProPublica reported on July 7, 2025. Makary resigned on May 12, 2026, and Kyle Diamantas, who had been deputy commissioner for food, became acting head of the agency.
- Moody Voted to Confirm Robert F. Kennedy Jr., Whose Department Dropped $2 Generic Drugs for Medicare, in February 2025. On February 13, 2025, Moody voted to confirm Robert F. Kennedy Jr. as secretary of health and human services. On March 12, 2025, his department's Medicare innovation center dropped the $2 Drug List model, which would have standardized cost sharing for certain generic drugs under Medicare Part D at $2.
- Moody Voted to Confirm Mehmet Oz, Whose Agency Ended a Drug-Plan Premium Program, in April 2025. On April 3, 2025, Moody voted to confirm Mehmet Oz to run the Centers for Medicare & Medicaid Services. In 2026 his agency ended a Part D premium demonstration; for 2027, all 4 million PDP enrollees who paid no monthly premium in 2026 will pay one unless they qualify for low-income help, changes KFF calls "possibly related" to the demonstration's end.
What the Drug-Price Votes Ashley Moody Cast Mean for Florida
- Medicare enrollees. Florida's 5,133,537 Medicare enrollees, 2,883,570 of them in Medicare Advantage, are the people for whom negotiated prices matter; the law Ashley Moody voted for exempts more drugs from negotiation, at an added cost to Medicare of $8.8 billion.
Frequently Asked Questions About Ashley Moody on Prescription drugs
What is Ashley Moody's record on prescription drug prices under Trump?
Ashley Moody voted for the One Big Beautiful Bill Act, which exempts more drugs from Medicare price negotiation at a cost of $8.8 billion. Moody voted against amendments to halve Medicare drug prices and to cap U.S. prices at European and Canadian levels, and voted to confirm Martin Makary, whose FDA lost drug-factory inspectors.
Did Ashley Moody vote to exempt more drugs from Medicare price negotiation?
Yes. Ashley Moody voted on July 1, 2025 for the One Big Beautiful Bill Act, whose orphan-drug change exempts more drugs from Medicare negotiation. The first ten negotiated prices took effect in 2026, and CMS estimated Medicare beneficiaries will save $1.5 billion that year.
Did Ashley Moody vote to make drug companies charge Americans what they charge Europeans and Canadians?
No. Ashley Moody voted on April 23, 2026 against waiving budget rules for an amendment to adopt Most Favored Nation drug pricing so that Americans pay no more than Europeans or Canadians; it got 49 votes, short of 60. The same day she voted against a study of the administration's confidential drug-price deals.
Last updated: 2026-10-25